GUNN & Co INVESTMENT MANAGEMENT INC. Acquires Shares of 90,341 Pfizer Inc. (NYSE:PFE)

GUNN & Co INVESTMENT MANAGEMENT INC. purchased a new position in shares of Pfizer Inc. (NYSE:PFE) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 90,341 shares of the biopharmaceutical company’s stock, valued at approximately $2,601,000.

Several other hedge funds have also recently modified their holdings of PFE. Capital Investment Advisory Services LLC increased its stake in Pfizer by 12.5% during the 4th quarter. Capital Investment Advisory Services LLC now owns 98,200 shares of the biopharmaceutical company’s stock worth $2,827,000 after buying an additional 10,931 shares in the last quarter. OLD National Bancorp IN increased its position in shares of Pfizer by 12.0% during the fourth quarter. OLD National Bancorp IN now owns 225,102 shares of the biopharmaceutical company’s stock worth $6,481,000 after purchasing an additional 24,165 shares in the last quarter. Brendel Financial Advisors LLC acquired a new position in Pfizer in the 4th quarter valued at $2,854,000. Commerzbank Aktiengesellschaft FI lifted its holdings in Pfizer by 5.0% in the 4th quarter. Commerzbank Aktiengesellschaft FI now owns 241,832 shares of the biopharmaceutical company’s stock valued at $6,962,000 after purchasing an additional 11,497 shares in the last quarter. Finally, PSI Advisors LLC boosted its stake in Pfizer by 19.1% during the 4th quarter. PSI Advisors LLC now owns 29,508 shares of the biopharmaceutical company’s stock worth $850,000 after purchasing an additional 4,729 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $27.81 on Friday. The firm has a 50-day simple moving average of $26.88 and a two-hundred day simple moving average of $28.21. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $40.37. The stock has a market cap of $157.48 billion, a PE ratio of -463.42, a P/E/G ratio of 1.18 and a beta of 0.63.

Pfizer (NYSE:PFE) last posted its earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.58%. The firm had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter last year, the firm earned $1.23 EPS. The firm’s revenue for the quarter was down 19.5% on a year-over-year basis. As a group, analysts forecast that Pfizer Inc. will post 2.36 EPS for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a yield of 6.04%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analyst Ratings Changes

Several research firms have recently weighed in on PFE. Guggenheim initiated coverage on shares of Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. Morgan Stanley raised their target price on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, BMO Capital Markets restated an “outperform” rating and issued a $36.00 target price (up from $33.00) on shares of Pfizer in a report on Thursday. Eleven analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average price target of $36.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.